Drug-Coated Balloon

Micell is developing a novel drug-coated balloon (DCB) to deliver sirolimus to the artery wall at the site of a percutaneous transluminal angioplasty (PTA) and/or stent implantation for peripheral and coronary indications. Micell's DCB consists of a proprietary fully-absorbable coating that targets prolonged delivery of a therapeutic dose of sirolimus for several weeks after a simple balloon catheter inflation at a target site. Sirolimus has been chosen for this device due to its demonstrated effectiveness as an anti-restenotic in vascular interventions as well as its broad therapeutic window - properties which may reduce risks or complications inherent with other drug-balloon combinations.

Micell's drug-coated balloon may be applicable in coronary and peripheral artery indications as well as other device-based drug delivery applications.